ABBV AbbVie Inc

  1. Stocks
  2. Healthcare
  3. NYSE: ABBV

Price (delayed)

$185.16

Market cap

$326.97B

P/E Ratio

54.94

Dividend/share

$6.13

EPS

$3.37

Enterprise value

$382.9B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate ...

Highlights
The quick ratio has grown by 14% from the previous quarter and by 9% YoY
The EPS has grown by 23% from the previous quarter but it has contracted by 21% YoY
The company's net income rose by 23% QoQ but it fell by 21% YoY
ABBV's P/E is 83% above its 5-year quarterly average of 29.6 and 21% above its last 4 quarters average of 44.8
AbbVie's equity has decreased by 40% YoY and by 23% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.abbvie.com/
Peers: PFE BMY LLY AMGN

Key stats

What are the main financial stats of ABBV
Market
Shares outstanding
1.77B
Market cap
$326.97B
Enterprise value
$382.9B
Valuations
Price to earnings (P/E)
54.94
Price to book (P/B)
40.85
Price to sales (P/S)
6.02
EV/EBIT
41.61
EV/EBITDA
21.45
EV/Sales
7.04
Earnings
Revenue
$54.4B
EBIT
$9.2B
EBITDA
$17.85B
Free cash flow
$21.89B
Per share
EPS
$3.37
Free cash flow per share
$12.37
Book value per share
$4.53
Revenue per share
$30.75
TBVPS
$30.09
Balance sheet
Total assets
$148.87B
Total liabilities
$140.83B
Debt
$74B
Equity
$8.01B
Working capital
-$2.65B
Liquidity
Debt to equity
9.24
Current ratio
0.94
Quick ratio
0.72
Net debt/EBITDA
3.13
Margins
EBITDA margin
32.8%
Gross margin
62.3%
Net margin
11%
Operating margin
23.5%
Efficiency
Return on assets
4.3%
Return on equity
55.3%
Return on invested capital
15.2%
Return on capital employed
8.6%
Return on sales
16.9%
Dividend
Dividend yield
3.31%
DPS
$6.13
Payout ratio
181.9%

ABBV stock price

How has the AbbVie stock price performed over time
Intraday
1.64%
1 week
7.45%
1 month
8.19%
1 year
30.49%
YTD
19.48%
QTD
7.95%

Financial performance

How have AbbVie's revenue and profit performed over time
Revenue
$54.4B
Gross profit
$33.88B
Operating income
$12.79B
Net income
$5.99B
Gross margin
62.3%
Net margin
11%
The company's net income rose by 23% QoQ but it fell by 21% YoY
The net margin rose by 22% since the previous quarter but it has declined by 18% year-on-year
The operating income has contracted by 21% YoY
The operating margin has declined by 18% year-on-year

Growth

What is AbbVie's growth rate over time

Valuation

What is AbbVie stock price valuation
ABBV P/E details
P/E
54.94
P/B
40.85
P/S
6.02
EV/EBIT
41.61
EV/EBITDA
21.45
EV/Sales
7.04
ABBV's P/E is 83% above its 5-year quarterly average of 29.6 and 21% above its last 4 quarters average of 44.8
The EPS has grown by 23% from the previous quarter but it has contracted by 21% YoY
ABBV's price to book (P/B) is 122% higher than its 5-year quarterly average of 18.1 and 51% higher than its last 4 quarters average of 26.7
AbbVie's equity has decreased by 40% YoY and by 23% from the previous quarter
ABBV's P/S is 38% above its 5-year quarterly average of 4.3 and 18% above its last 4 quarters average of 5.0
ABBV's revenue is down by 4.1% year-on-year

Efficiency

How efficient is AbbVie business performance
The ROE has grown by 38% from the previous quarter and by 11% YoY
AbbVie's return on assets has decreased by 20% YoY but it has increased by 19% QoQ
The ROS has grown by 16% from the previous quarter but it has contracted by 12% YoY
AbbVie's ROIC has increased by 15% from the previous quarter but it has decreased by 8% YoY

Dividends

What is ABBV's dividend history
Dividend details
DPS
$6.13
Dividend yield
3.31%
Payout ratio
181.9%
Recent dividends

Financial health

How did AbbVie financials performed over time
AbbVie's total assets is 6% higher than its total liabilities
The total liabilities rose by 16% year-on-year and by 13% since the previous quarter
The quick ratio has grown by 14% from the previous quarter and by 9% YoY
The company's debt to equity has surged by 97% YoY and by 61% QoQ
AbbVie's equity has decreased by 40% YoY and by 23% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.